Sign in Register

Drug class

Cephalosporins - 4th Generation

Fourth-generation cephalosporins are an advanced subclass of broad-spectrum, parenteral beta-lactam antibiotics, most prominently represented by cefepime. Read more about Cephalosporins - 4th Generation

12 drugs in this class 11 manufacturers

Related classes & indications

Antimalarial DrugsAnti-infectives · 223 prescription drugs Antiprotozoal AgentsAnti-infectives · 102 prescription drugs

Showing 1–9 of 12 drugs

Sort

CEFEPIME (cefepime HCl in iso-osmotic dextrose)

BETA-LACTAMS · FEBRILE NEUTROPENIC PATIENT PRESUMED INFECTION TREATMENT ·+26

Baxter Healthcare Company

CEFEPIME-DEXTROSE (cefepime HCl in dextrose 5 % in water)

BETA-LACTAMS · FEBRILE NEUTROPENIC PATIENT PRESUMED INFECTION TREATMENT ·+26

B. Braun Medical

CEFEPIME HCL

BETA-LACTAMS · FEBRILE NEUTROPENIC PATIENT PRESUMED INFECTION TREATMENT ·+26

SAGENT PHARMACE

CEFEPIME HCL

BETA-LACTAMS · FEBRILE NEUTROPENIC PATIENT PRESUMED INFECTION TREATMENT ·+26

APOTEX/NOVAPLUS

CEFEPIME HCL

BETA-LACTAMS · FEBRILE NEUTROPENIC PATIENT PRESUMED INFECTION TREATMENT ·+26

WG CRITICAL CAR

CEFEPIME HCL

BETA-LACTAMS · FEBRILE NEUTROPENIC PATIENT PRESUMED INFECTION TREATMENT ·+26

SAGENT/PREMIERP

MAXIPIME (cefepime HCl)

BETA-LACTAMS · FEBRILE NEUTROPENIC PATIENT PRESUMED INFECTION TREATMENT ·+26

Hospira

CEFEPIME HCL

BETA-LACTAMS · FEBRILE NEUTROPENIC PATIENT PRESUMED INFECTION TREATMENT ·+26

FRESENIUS KABI

CEFEPIME HCL

BETA-LACTAMS · FEBRILE NEUTROPENIC PATIENT PRESUMED INFECTION TREATMENT ·+26

SAMSON MEDICAL

Filter & compare in the drug finder → Opens the drug finder with Cephalosporins - 4th Generation preselected. Add indication or manufacturer filters there.

About Cephalosporins - 4th Generation.

Fourth-generation cephalosporins are an advanced subclass of broad-spectrum, parenteral beta-lactam antibiotics, most prominently represented by cefepime.

They exert bactericidal activity by binding to penicillin-binding proteins to disrupt bacterial cell wall peptidoglycan synthesis, while their unique zwitterionic structure enhances outer-membrane penetration and stability against hydrolysis by AmpC and other beta-lactamases.

These agents offer expanded coverage against both gram-positive pathogens, such as methicillin-susceptible *Staphylococcus aureus* and *Streptococcus pneumoniae*, and difficult-to-treat gram-negative organisms, including *Pseudomonas aeruginosa* and Enterobacterales.

Consequently, they serve as critical empirical and targeted therapies for severe, nosocomial infections, including hospital-acquired pneumonia, complicated intra-abdominal and urinary tract infections, skin and skin-structure infections, and febrile neutropenia.

nih.gov
Fourth-generation cephalosporins are an advanced subclass of broad-spectrum, parenteral beta-lactam antibiotics, most prominently represented by cefepime
nih.gov
Fourth-generation cephalosporins are an advanced subclass of broad-spectrum, parenteral beta-lactam antibiotics, most prominently represented by cefepime They exert bactericidal activity by binding to penicillin-binding proteins to disrupt bacterial cell wall peptidoglycan synthesis, while their unique zwitterionic structure enhances outer-membrane penetration and stability against hydrolysis by AmpC and other beta-lactamases These agents offer expanded coverage against both gram-positive pathog...
nih.gov
They exert bactericidal activity by binding to penicillin-binding proteins to disrupt bacterial cell wall peptidoglycan synthesis, while their unique zwitterionic structure enhances outer-membrane penetration and stability against hydrolysis by AmpC and other beta-lactamases
nih.gov
They exert bactericidal activity by binding to penicillin-binding proteins to disrupt bacterial cell wall peptidoglycan synthesis, while their unique zwitterionic structure enhances outer-membrane penetration and stability against hydrolysis by AmpC and other beta-lactamases
nih.gov
These agents offer expanded coverage against both gram-positive pathogens, such as methicillin-susceptible *Staphylococcus aureus* and *Streptococcus pneumoniae*, and difficult-to-treat gram-negative organisms, including *Pseudomonas aeruginosa* and Enterobacterales
nih.gov
Consequently, they serve as critical empirical and targeted therapies for severe, nosocomial infections, including hospital-acquired pneumonia, complicated intra-abdominal and urinary tract infections, skin and skin-structure infections, and febrile neutropenia
nih.gov
Consequently, they serve as critical empirical and targeted therapies for severe, nosocomial infections, including hospital-acquired pneumonia, complicated intra-abdominal and urinary tract infections, skin and skin-structure infections, and febrile neutropenia